Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation.

Slides:



Advertisements
Similar presentations
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Advertisements

Stephanie J. Lee, Loretta A. Williams 
A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,
Strong Association between Respiratory Viral Infection Early after Hematopoietic Stem Cell Transplantation and the Development of Life-Threatening Acute.
Clinical Evaluation of Oral Chronic Graft-Versus-Host Disease
Incidence and Prognostic Value of Eosinophilia in Chronic Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation  Imran Ahmad,
Vaccination of Children following Allogeneic Stem Cell Transplantation
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Validation of National Institutes of Health Global Scoring System for Chronic Graft- Versus-Host Disease (GVHD) According to Overall and GVHD-Specific.
Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.
A Multicenter Pilot Evaluation of the National Institutes of Health Chronic Graft-versus- Host Disease (cGVHD) Therapeutic Response Measures: Feasibility,
Salivary Gland Involvement in Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation  Matin M. Imanguli,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:
Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia  Laura Grein Cavalcanti, Renata L. Fuentes Araújo,
Sabina Kersting, Leo F. Verdonck 
Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease  Paul A. Carpenter, Paul Hoffmeister, Charles.
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Betty T. Tran, Abigail Halperin, Jason W. Chien 
National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established.
Stephanie J. Lee, Loretta A. Williams 
Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation  Bipin N. Savani, Theresa Donohue,
Symptom Distress Predicts Long-Term Health and Well-Being in Allogeneic Stem Cell Transplantation Survivors  Margaret F. Bevans, Sandra A. Mitchell, John.
Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J
Lymphocyte Phenotype during Therapy for Acute Graft-versus-Host Disease: A Brief Report from BMT-CTN 0302  Javier Bolaños-Meade, Juan Wu, Brent R. Logan,
Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study 
Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review  Filippo.
Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation  Philipp Yorck Herzberg, Pia.
Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria  Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease
Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation  Jan Storek,
A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse  Zeyad Kanaan, MD, William Tse, MD, FACP 
Hematopoietic Cell Transplantation for Acute Leukemia and Advanced Myelodysplastic Syndrome in Fanconi Anemia  Richard Mitchell, Todd Defor, John E. Wagner,
Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert.
Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation 
Folinic Acid Supplementation in Higher Doses is Associated with Graft Rejection in Pediatric Hematopoietic Stem Cell Transplantation  Henric Lindqvist,
Can Only Partial T-Cell Depletion of the Graft before Hematopoietic Stem Cell Transplantation Mitigate Graft-versus-Host Disease While Preserving a Graft-versus-
Incidence of Post-Transplant Bacterial Foodborne Pathogens in Hematopoietic Stem Cell Transplant Patients  Nicole Boyle, Sara Podczervinski, Kim Jordan,
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Rammurti.
Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.
Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors  Annelies Billen, J. Alejandro Madrigal,
NCI, NHLBI/PBMTC First International Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Health-Related Quality of Life, Functional,
Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data  Brent R. Logan, Mei-Jie Zhang,
Mohammad Alhyari, M. D. , Aymen Bukannan, M. D. , Kimberly Brown, M. D
What is quality in a transplant program?
Chronic GVHD and Pretransplantation Abnormalities in Pulmonary Function Are the Main Determinants Predicting Worsening Pulmonary Function in Long-term.
Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.
Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews  Emily C. Merkel, Sandra A. Mitchell,
Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.
John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos 
A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.
Blood and Marrow Transplant Handbook
Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.
Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.
Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease  Haydar Frangoul, Li.
Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after.
Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma  Tanya M. Wildes, Kristan M. Augustin, Diane.
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  Andy I. Chen, Alex McMillan,
Donald R. Dengel, Aaron S. Kelly, Lei Zhang, Qi Wang, James S
Biology of Blood and Marrow Transplantation
Presentation transcript:

Oral Symptom Intensity, Health-Related Quality of Life, and Correlative Salivary Cytokines in Adult Survivors of Hematopoietic Stem Cell Transplantation with Oral Chronic Graft-versus-Host Disease  Jane M. Fall-Dickson, Sandra A. Mitchell, Susan Marden, Edward S. Ramsay, Jean-Pierre Guadagnini, Tianxia Wu, Lena St. John, Steven Z. Pavletic  Biology of Blood and Marrow Transplantation  Volume 16, Issue 7, Pages 948-956 (July 2010) DOI: 10.1016/j.bbmt.2010.01.017 Copyright © 2010 Terms and Conditions

Figure 1 Erythema and ulceration/pseudomembrane in a subject with oral cGVHD. Biology of Blood and Marrow Transplantation 2010 16, 948-956DOI: (10.1016/j.bbmt.2010.01.017) Copyright © 2010 Terms and Conditions

Figure 2 Scatterplots of individual scores of the (A) FACT-G total version 4 and (B) FACT-G PWB, EWB, SWB, and FWB subscales by oral dryness, classified as none (0), mild (1-3), moderate (4-6), or severe (7-10); n = 29. Higher FACT-G total score (range, 0-108) and higher PWB, SWB, FWB (range 0-28), and EWB (range, 0-24) scores represent better HRQL. Biology of Blood and Marrow Transplantation 2010 16, 948-956DOI: (10.1016/j.bbmt.2010.01.017) Copyright © 2010 Terms and Conditions